Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Feb 23:18:503-506.
doi: 10.2147/PPA.S451007. eCollection 2024.

Real-Time Experience of Abrocitinib for the Treatment of Mucous Membrane Pemphigoid: A Case Report

Yan Teng  1 , Mingyang Ren  1 , Xianhong Yang  1 , Wei Lu  1 , Xiaohua Tao  1
Affiliations
Case Reports

Real-Time Experience of Abrocitinib for the Treatment of Mucous Membrane Pemphigoid: A Case Report

Yan Teng et al. Patient Prefer Adherence. .

Abstract

Background: Mucous membrane pemphigoid (MMP), a rare autoimmune vesiculous and erosive disorder, may affect multiple mucous membranes, with the oral cavity being the most commonly affected site. Its treatment depends on the site(s) of mucosal involvement and disease severity.

Patients and methods: A 62-year-old female patient with MMP that predominantly involved the oral cavity strongly rejected systemic corticosteroid or immunosuppressive agents and was successfully treated with abrocitinib, a highly selective JAK-1 inhibitor with a good safety profile.

Results: The case demonstrated good efficacy and safety profile of abrocitinib for the treatment of MMP with predominant oral involvement.

Conclusion: Abrocitinib is a promising agent for the treatment of MMP with oral involvement.

Keywords: JAK inhibitor; abrocitinib; mucous membrane pemphigoid.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest and no payment for expert testimony for this work.

Figures

Figure 1
Figure 1
Mucous membrane pemphigoid with the oral predominant response to abrocitinib therapy. (a) before the abrocitinib therapy. (b) Two weeks later after the abrocitinib therapy. (c) Four weeks later after the abrocitinib therapy.
Figure 2
Figure 2
(a) A cleavage between the epidermis and dermis with a few infiltrations of eosinophils and lymphocytes. (b) Direct immunofluorescence showed IgG was deposited linearly in the basement membrane zone.
See this image and copyright information in PMC

References

    1. Chan LS, Ahmed AR, Anhalt GJ, et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol. 2002;138(3):370–379. - PubMed
    1. Abdat R, Waldman RA, de Bedout V, et al. Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series. J Am Acad Dermatol. 2020;83(1):46–52. - PubMed
    1. Napolitano M, Fabbrocini G, Genco L, et al. Rapid improvement in pruritus in atopic dermatitis patients treated with upadacitinib: a real-life experience. J Eur Acad Dermatol Venereol. 2022;36(9):1497–1498. - PubMed
    1. Martora F, Scalvenzi M, Ruggiero A, et al. Hidradenitis suppurativa and JAK inhibitors: a review of the published literature. Medicina. 2023;59(4):1. - PMC - PubMed
    1. Eichenfield LF, Flohr C, Sidbury R, et al. Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: the JADE TEEN randomized clinical trial. JAMA Dermatol. 2021;157(10):1165–1173. - PMC - PubMed

Publication types